These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 32602383)

  • 1. Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis.
    Fu Z; Xu Y; Cai C
    J Asthma; 2021 Oct; 58(10):1350-1358. PubMed ID: 32602383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation.
    Norman G; Faria R; Paton F; Llewellyn A; Fox D; Palmer S; Clifton I; Paton J; Woolacott N; McKenna C
    Health Technol Assess; 2013 Nov; 17(52):1-342. PubMed ID: 24267198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
    Tarraf HN; Masoud HH; Zidan M; Wahba B
    J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review.
    Corren J; Kavati A; Ortiz B; Colby JA; Ruiz K; Maiese BA; Cadarette SM; Panettieri RA
    Allergy Asthma Proc; 2017 Jul; 38(4):250-263. PubMed ID: 28631599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
    Hanania NA; Alpan O; Hamilos DL; Condemi JJ; Reyes-Rivera I; Zhu J; Rosen KE; Eisner MD; Wong DA; Busse W
    Ann Intern Med; 2011 May; 154(9):573-82. PubMed ID: 21536936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
    Teach SJ; Gill MA; Togias A; Sorkness CA; Arbes SJ; Calatroni A; Wildfire JJ; Gergen PJ; Cohen RT; Pongracic JA; Kercsmar CM; Khurana Hershey GK; Gruchalla RS; Liu AH; Zoratti EM; Kattan M; Grindle KA; Gern JE; Busse WW; Szefler SJ
    J Allergy Clin Immunol; 2015 Dec; 136(6):1476-1485. PubMed ID: 26518090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab in Japanese children with severe allergic asthma uncontrolled with standard therapy.
    Odajima H; Ebisawa M; Nagakura T; Fujisawa T; Akasawa A; Ito K; Doi S; Yamaguchi K; Katsunuma T; Kurihara K; Kondo N; Sugai K; Nambu M; Hoshioka A; Yoshihara S; Sato N; Seko N; Nishima S
    Allergol Int; 2015 Oct; 64(4):364-70. PubMed ID: 26433533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of omalizumab treatment in children with severe asthma: Report of a local experience.
    Giubergia V; Ramírez Farías MJ; Pérez V; Crespi N; Castaños C
    Arch Argent Pediatr; 2019 Apr; 117(2):e115-e120. PubMed ID: 30869489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents.
    Rodrigo GJ; Neffen H
    Pediatr Allergy Immunol; 2015 Sep; 26(6):551-6. PubMed ID: 25963882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.
    Chapman KR; Albers FC; Chipps B; Muñoz X; Devouassoux G; Bergna M; Galkin D; Azmi J; Mouneimne D; Price RG; Liu MC
    Allergy; 2019 Sep; 74(9):1716-1726. PubMed ID: 31049972
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on omalizumab in allergic asthma.
    Bang LM; Plosker GL
    BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 'Real-life' effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review.
    Abraham I; Alhossan A; Lee CS; Kutbi H; MacDonald K
    Allergy; 2016 May; 71(5):593-610. PubMed ID: 26644231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults.
    Chauhan BF; Chartrand C; Ducharme FM
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD009611. PubMed ID: 23450606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab: an update on efficacy and safety in moderate-to-severe allergic asthma.
    Chipps BE; Figliomeni M; Spector S
    Allergy Asthma Proc; 2012; 33(5):377-85. PubMed ID: 23026179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term "real-life" safety of omalizumab in patients with severe uncontrolled asthma: A nine-year study.
    Di Bona D; Fiorino I; Taurino M; Frisenda F; Minenna E; Pasculli C; Kourtis G; Rucco AS; Nico A; Albanesi M; Giliberti L; D'Elia L; Caiaffa MF; Macchia L
    Respir Med; 2017 Sep; 130():55-60. PubMed ID: 29206634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A step-down protocol for omalizumab treatment in oral corticosteroid-dependent allergic asthma patients.
    Domingo C; Pomares X; Navarro A; Amengual MJ; Montón C; Sogo A; Mirapeix RM
    Br J Clin Pharmacol; 2018 Feb; 84(2):339-348. PubMed ID: 29044640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults.
    Chauhan BF; Chartrand C; Ducharme FM
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009611. PubMed ID: 23235678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.